{
    "clinical_study": {
        "@rank": "126046", 
        "arm_group": {
            "arm_group_label": "Risperidone", 
            "arm_group_type": "Experimental", 
            "description": "Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of long acting injectable\n      microspheres of risperidone in participants with schizophrenia (psychiatric disorder with\n      symptoms of emotional instability, detachment from reality, often with delusions and\n      hallucinations, and withdrawal into the self), schizophreniform or schizoaffective disorders\n      (disorders in which there is a loss of ego boundaries or a gross impairment in reality\n      testing with delusions or prominent hallucinations)."
        }, 
        "brief_title": "An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "Risperidone 25 milligram (mg) was administered as intramuscular injection (injection of a substance into a muscle) every 2 weeks up to 6 months", 
                        "title": "Risperidone"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "79"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "12.4", 
                                            "@value": "43.0"
                                        }
                                    }
                                }
                            }, 
                            "description": "Safety set (SS) population (N=79) included all participants who received at least 1 dose of study drug.", 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "Years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "32"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "47"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "description": "Safety set (SS) population (N=79) included all participants who received at least 1 dose of study drug.", 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "Participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "All the information generated through services from the Principal Investigator (PI), the Sponsor has the rights to publish the data without previous consent from the PI.\nThe PI must not publish completely or partially any results from the study, without previous authorization from the Sponsor."
            }, 
            "limitations_and_caveats": "The planned sample size was not reached and a high dropout rate of participants  was observed. Due to the high number of protocol violations, analysis was performed as intention-to-treat instead of per protocol as was planned.", 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening. Change at Week 26 score is calculated as Baseline score minus Week 26 score.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Risperidone 25 milligram (mg) was administered as intramuscular injection (injection of a substance into a muscle) every 2 weeks up to 6 months", 
                                "title": "Risperidone"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "78"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "15.8", 
                                                        "@value": "68.9"
                                                    }
                                                }, 
                                                "sub_title": "Baseline (n=78)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "17.1", 
                                                        "@value": "28.1"
                                                    }
                                                }, 
                                                "sub_title": "Change at Week 26 (n=66)"
                                            }
                                        ]
                                    }, 
                                    "description": "The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening. Change at Week 26 score is calculated as Baseline score minus Week 26 score.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26", 
                                    "units": "Units on a scale"
                                }
                            ]
                        }, 
                        "population": "The Intent-to-treat (ITT) population included all the participants who received at least 1 dose of study medication and had at least 1 follow-up visit. Here 'n' signifies number of participants evaluable for this outcome measure at specific time point.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Week 26", 
                        "title": "Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to \"Normal, not at all ill\" and a rating of 7 is equivalent to \"Among the most extremely ill participants\", higher scores indicate worsening.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Risperidone 25 milligram (mg) was administered as intramuscular injection (injection of a substance into a muscle) every 2 weeks up to 6 months", 
                                "title": "Risperidone"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "78"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "4.0", 
                                                        "@value": "4.2"
                                                    }
                                                }, 
                                                "sub_title": "Baseline (n=78)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "3.0", 
                                                        "@value": "2.9"
                                                    }
                                                }, 
                                                "sub_title": "Week 26 (n=66)"
                                            }
                                        ]
                                    }, 
                                    "description": "The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to \"Normal, not at all ill\" and a rating of 7 is equivalent to \"Among the most extremely ill participants\", higher scores indicate worsening.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Clinical Global Impressions (CGI) - Disease Severity Score", 
                                    "units": "Units on a scale"
                                }
                            ]
                        }, 
                        "population": "The Intent-to-treat (ITT) population included all the participants who received at least 1 dose of study medication and had at least 1 follow-up visit. Here 'n' signifies number of participants evaluable for this outcome measure at specific time point.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Week 26", 
                        "title": "Clinical Global Impressions (CGI) - Disease Severity Score", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "The SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: vitality, physical function, social function, physical role, emotional role, bodily pain, general health, mental health. Each item is scored on a scale ranging from 0-100 (100=highest level of functioning).", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Risperidone 25 milligram (mg) was administered as intramuscular injection (injection of a substance into a muscle) every 2 weeks up to 6 months", 
                                "title": "Risperidone"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "78"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "21.7", 
                                                        "@value": "78.3"
                                                    }
                                                }, 
                                                "sub_title": "Baseline; Physical function (n=78)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "13.8", 
                                                        "@value": "90.5"
                                                    }
                                                }, 
                                                "sub_title": "Week 26; Physical function (n=66)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "46.5", 
                                                        "@value": "41.0"
                                                    }
                                                }, 
                                                "sub_title": "Baseline; Physical role (n=78)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "41.0", 
                                                        "@value": "75.4"
                                                    }
                                                }, 
                                                "sub_title": "Week 26; Physical role (n=66)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "19.8", 
                                                        "@value": "86.2"
                                                    }
                                                }, 
                                                "sub_title": "Baseline; Body pain (n=78)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "11.8", 
                                                        "@value": "94.7"
                                                    }
                                                }, 
                                                "sub_title": "Week 26; Body pain (n=66)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "18.3", 
                                                        "@value": "51.7"
                                                    }
                                                }, 
                                                "sub_title": "Baseline; General health (n=78)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "12.0", 
                                                        "@value": "67.8"
                                                    }
                                                }, 
                                                "sub_title": "Week 26; General health (n=66)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "16.8", 
                                                        "@value": "51.7"
                                                    }
                                                }, 
                                                "sub_title": "Baseline; Vitality (n=78)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "11.5", 
                                                        "@value": "58.6"
                                                    }
                                                }, 
                                                "sub_title": "Week 26; Vitality (n=66)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "20.4", 
                                                        "@value": "49.0"
                                                    }
                                                }, 
                                                "sub_title": "Baseline; Social function (n=78)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "18.1", 
                                                        "@value": "74.1"
                                                    }
                                                }, 
                                                "sub_title": "Week 26; Social function (n=66)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "46.0", 
                                                        "@value": "32.1"
                                                    }
                                                }, 
                                                "sub_title": "Baseline; Emotional role (n=78)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "42.3", 
                                                        "@value": "73.2"
                                                    }
                                                }, 
                                                "sub_title": "Week 26; Emotional role (n=66)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "13.8", 
                                                        "@value": "50.7"
                                                    }
                                                }, 
                                                "sub_title": "Baseline; Mental health (n=78)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "12.8", 
                                                        "@value": "59.9"
                                                    }
                                                }, 
                                                "sub_title": "Week 26; Mental health (n=66)"
                                            }
                                        ]
                                    }, 
                                    "description": "The SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: vitality, physical function, social function, physical role, emotional role, bodily pain, general health, mental health. Each item is scored on a scale ranging from 0-100 (100=highest level of functioning).", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Short Form-36 (SF-36) - Quality of Life Score", 
                                    "units": "Units on a scale"
                                }
                            ]
                        }, 
                        "population": "The ITT population included all the participants who received at least 1 dose of study medication and had at least 1 follow-up visit. Here, 'n' signifies number of participants evaluable for this outcome measure at specific time point.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Week 26", 
                        "title": "Short Form-36 (SF-36) - Quality of Life Score", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "The GAF is a 100-point tool to measure overall psychological, social and occupational functioning of adults. The higher score range (91 to 100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1 to 10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Risperidone 25 milligram (mg) was administered as intramuscular injection (injection of a substance into a muscle) every 2 weeks up to 6 months", 
                                "title": "Risperidone"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "78"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "14.2", 
                                                        "@value": "56.5"
                                                    }
                                                }, 
                                                "sub_title": "Baseline (n=78)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "11.7", 
                                                        "@value": "69.4"
                                                    }
                                                }, 
                                                "sub_title": "Week 26 (n=66)"
                                            }
                                        ]
                                    }, 
                                    "description": "The GAF is a 100-point tool to measure overall psychological, social and occupational functioning of adults. The higher score range (91 to 100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1 to 10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Global Assessment of Functioning (GAF) Score", 
                                    "units": "Units on a scale"
                                }
                            ]
                        }, 
                        "population": "The ITT population included all the participants who received at least 1 dose of study medication and had at least 1 follow-up visit. Here, 'n' signifies number of participants evaluable for this outcome measure at specific time point.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Week 26", 
                        "title": "Global Assessment of Functioning (GAF) Score", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Participants\u2019 were assessed for their satisfaction with the current antipsychotic treatment on a 5-point scale/questionnaire: very good, good, reasonable, moderate or poor.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Risperidone 25 milligram (mg) was administered as intramuscular injection (injection of a substance into a muscle) every 2 weeks up to 6 months", 
                                "title": "Risperidone"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "78"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "2"
                                                    }
                                                }, 
                                                "sub_title": "Baseline; Very good (n=78)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "16"
                                                    }
                                                }, 
                                                "sub_title": "Week 26; Very good (n=66)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "13"
                                                    }
                                                }, 
                                                "sub_title": "Baseline; Good (n=78)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "40"
                                                    }
                                                }, 
                                                "sub_title": "Week 26; Good (n=66)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "42"
                                                    }
                                                }, 
                                                "sub_title": "Baseline; Moderate (n=78)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "10"
                                                    }
                                                }, 
                                                "sub_title": "Week 26; Moderate (n=66)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "19"
                                                    }
                                                }, 
                                                "sub_title": "Baseline; Poor (n=78)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "Baseline; Very poor (n=78)"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "Baseline; No available (n=78)"
                                            }
                                        ]
                                    }, 
                                    "description": "Participants\u2019 were assessed for their satisfaction with the current antipsychotic treatment on a 5-point scale/questionnaire: very good, good, reasonable, moderate or poor.", 
                                    "param": "Number", 
                                    "title": "Patient Satisfaction With Treatment", 
                                    "units": "Participants"
                                }
                            ]
                        }, 
                        "population": "The ITT population included all the participants who received at least 1 dose of study medication and had at least 1 follow-up visit. Here, 'n' signifies number of participants evaluable for this outcome measure at specific time point.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline and Week 26", 
                        "title": "Patient Satisfaction With Treatment", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "An ESRS scale is used to assess the extrapyramidal symptoms attributable to antipsychotics. It consists of 8 items to assess individual symptoms and each item is assessed from 0 (none, absent) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 severe). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Risperidone 25 milligram (mg) was administered as intramuscular injection (injection of a substance into a muscle) every 2 weeks up to 6 months", 
                                "title": "Risperidone"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "78"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "9.6", 
                                                        "@value": "12.9"
                                                    }
                                                }, 
                                                "sub_title": "Baseline"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "5.1", 
                                                        "@value": "9.2"
                                                    }
                                                }, 
                                                "sub_title": "Week 26"
                                            }
                                        ]
                                    }, 
                                    "description": "An ESRS scale is used to assess the extrapyramidal symptoms attributable to antipsychotics. It consists of 8 items to assess individual symptoms and each item is assessed from 0 (none, absent) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 severe). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Extrapyramidal Symptom Rating Scale (ESRS) Score", 
                                    "units": "Units on a scale"
                                }
                            ]
                        }, 
                        "population": "Safety set (SS) population (N=79) included all participants who received at least 1 dose of study drug. Here, 'N' (number of participants analyzed) signifies those participants who were evaluable for this measure.", 
                        "safety_issue": "Yes", 
                        "time_frame": "Baseline and Week 26", 
                        "title": "Extrapyramidal Symptom Rating Scale (ESRS) Score", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "Risperidone 25 milligram (mg) was administered as intramuscular injection (injection of a substance into a muscle) every 2 weeks up to 6 months", 
                        "title": "Risperidone"
                    }
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Adverse Event"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "4", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Lost to Follow-up"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "8", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Withdrawal by Subject"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Started but not treated"
                                }
                            ]
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "80", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "79", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Treated"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "66", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "14", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }
            }, 
            "point_of_contact": {
                "email": "dmuschet@its.jnj.com", 
                "name_or_title": "Medical Manager Neurosciences", 
                "organization": "Janssen. Pharmaceutical Companies of Johnson and Johnson", 
                "phone": "+507-3989740"
            }, 
            "reported_events": {
                "desc": "Safety set (SS) population (N=79) included all participants who received at least 1 dose of study drug.", 
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "Risperidone 25 milligram (mg) was administered as intramuscular injection (injection of a substance into a muscle) every 2 weeks up to 6 months", 
                        "title": "Risperidone"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "79"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "79"
                                        }, 
                                        "sub_title": "Extrapyramidal disorder"
                                    }
                                }, 
                                "title": "Nervous system disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA V 10.0", 
                    "frequency_threshold": "0"
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "79"
                                        }, 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "79"
                                        }, 
                                        "sub_title": "Psychotic disorder"
                                    }
                                }, 
                                "title": "Psychiatric disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA V 10.0"
                }
            }
        }, 
        "completion_date": {
            "#text": "February 2009", 
            "@type": "Actual"
        }, 
        "condition": [
            "Schizophrenia", 
            "Schizophreniform Disorder", 
            "Schizoaffective Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Psychotic Disorders", 
                "Schizophrenia"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label (all people know the identity of the intervention), longitudinal\n      (participants are followed over time with continuous or repeated monitoring of risk factors\n      or health-outcomes), non-randomized (a clinical trial in which the participants are not\n      assigned by chance to different treatment groups), single-center study to evaluate the\n      efficacy and safety of long acting microspheres of risperidone in adult participants with\n      schizophrenia, schizophreniform or schizoaffective disorders. The duration of this study\n      will be 12 months and duration of treatment will be 6 months. The study will include 4\n      visits: Baseline, and 3 follow-up visits including Week 4, 12 and 26. All eligible\n      participants will be treated with risperidone 25 milligram (mg) intramuscular injection\n      (injection of a substance into a muscle) for every two weeks up to 6 months. Participants\n      with persistent symptoms and/or requiring higher doses of antipsychotics (agents that\n      control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic\n      symptoms, and exert a quieting effect) will be initiated with higher doses of risperidone.\n      Doses will be adjusted according to the response of the treatment. Efficacy and safety of\n      the participants will be primarily evaluated by Positive and Negative Syndromes Scale\n      (PANSS) and Extrapyramidal Symptom Rating Scale (ESRS), respectively. Participants' quality\n      of life and safety will be monitored throughout the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Symptomatically stable participants defined as a) participants with treatment on\n             outpatient and inpatient basis for at least 4 weeks before entering the study, and b)\n             Positive and Negative Syndrome Scale (PANSS) Positive Subscale Score less than or\n             equal to (<= ) 3 (1-7), including conceptual disorganization, suspicion,\n             hallucinatory conduct and delirium (state of violent mental agitation)\n\n          -  Participants under antipsychotic treatment with extrapyramidal symptoms, persistent\n             negative symptoms or lack of adherence defined as irregular administration  of\n             medication in the last 2 weeks\n\n          -  Participants who have given their informed consent in writing, or at least, by their\n             family member or personal representative\n\n        Exclusion Criteria:\n\n          -  Participants taking first antipsychotic treatment in his/her life\n\n          -  Participants with any other psychotic disorder different to the previously mentioned\n             in the inclusion criteria\n\n          -  Pregnant or nursing women\n\n          -  History of neuroleptic malignant syndrome (potentially fatal syndrome associated\n             primarily with the use of antipsychotic drugs and clinical features include diffuse\n             muscle rigidity, tremor, high fever) or current symptoms of tardive dyskinesia (a\n             neurological disorder characterized by involuntary movements of the face and jaw)\n\n          -  Participants with known intolerance or lack of response to risperidone"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 22, 2013", 
        "firstreceived_results_date": "May 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01855074", 
            "org_study_id": "CR014845", 
            "secondary_id": "RISSCH4186"
        }, 
        "intervention": {
            "arm_group_label": "Risperidone", 
            "description": "Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.", 
            "intervention_name": "Risperidone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antipsychotic Agents", 
                "Risperidone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Schizophrenia", 
            "Schizophreniform Disorder", 
            "Schizoaffective Disorder", 
            "Risperidone", 
            "Risperdal consta"
        ], 
        "lastchanged_date": "August 6, 2013", 
        "number_of_arms": "1", 
        "official_title": "Evaluation of Efficacy and Safety of Risperidone in Long-acting Microspheres in Patients With Schizophrenia, Schizophreniform or Schizoaffective Disorders Diagnosed According to the DSM-IV Criteria, After Switching Treatment With Any Antipsychotic Therapy With Long-acting Microspheres of Risperidone", 
        "overall_official": {
            "affiliation": "Janssen-Cilag Ltd.", 
            "last_name": "Janssen-Cilag Ltd. Clinical trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Venezuela: Ministry of Health and Social Development", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening. Change at Week 26 score is calculated as Baseline score minus Week 26 score.", 
            "measure": "Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 26", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 26"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01855074"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to \"Normal, not at all ill\" and a rating of 7 is equivalent to \"Among the most extremely ill participants\", higher scores indicate worsening.", 
                "measure": "Clinical Global Impressions (CGI) - Disease Severity Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "description": "The SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: vitality, physical function, social function, physical role, emotional role, bodily pain, general health, mental health. Each item is scored on a scale ranging from 0-100 (100=highest level of functioning).", 
                "measure": "Short Form-36 (SF-36) - Quality of Life Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "description": "The GAF is a 100-point tool to measure overall psychological, social and occupational functioning of adults. The higher score range (91 to 100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1 to 10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.", 
                "measure": "Global Assessment of Functioning (GAF) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "description": "Participants' were assessed for their satisfaction with the current antipsychotic treatment on a 5-point scale/questionnaire: very good, good, reasonable, moderate or poor.", 
                "measure": "Patient Satisfaction With Treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "description": "An ESRS scale is used to assess the extrapyramidal symptoms attributable to antipsychotics. It consists of 8 items to assess individual symptoms and each item is assessed from 0 (none, absent) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 severe). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia.", 
                "measure": "Extrapyramidal Symptom Rating Scale (ESRS) Score", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Week 26"
            }
        ], 
        "source": "Janssen-Cilag Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen-Cilag Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2007", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}